Prophylactic Surgery to Reduce the Risk of Gynecologic Cancers in the Lynch Syndrome

Size: px
Start display at page:

Download "Prophylactic Surgery to Reduce the Risk of Gynecologic Cancers in the Lynch Syndrome"

Transcription

1 original article Prophylactic Surgery to Reduce the Risk of Gynecologic Cancers in the Lynch Syndrome Kathleen M. Schmeler, M.D., Henry T. Lynch, M.D., Lee-may Chen, M.D., Mark F. Munsell, M.S., Pamela T. Soliman, M.D., Mary Beth Clark, M.S.W., Molly S. Daniels, M.S., Kristin G. White, B.S., Stephanie G. Boyd-Rogers, R.N., Peggy G. Conrad, M.S., Kathleen Y. Yang, M.D., Mary M. Rubin, Ph.D., Charlotte C. Sun, Dr.P.H., Brian M. Slomovitz, M.D., David M. Gershenson, M.D., and Karen H. Lu, M.D. Abstract Background Women with the Lynch syndrome (hereditary nonpolyposis colorectal cancer) have a 40 to 60 percent lifetime risk of endometrial cancer and a 10 to 12 percent lifetime risk of ovarian cancer. The benefit of prophylactic gynecologic surgery for women with this syndrome has been uncertain. We designed this study to determine the reduction in the risk of gynecologic cancers associated with prophylactic hysterectomy and bilateral salpingo-oophorectomy in women with the Lynch syndrome. Methods Three hundred fifteen women with documented germ-line mutations associated with the Lynch syndrome were identified. Women who had undergone prophylactic hysterectomy (61 women) and women who had undergone prophylactic bilateral salpingo-oophorectomy (47 women) were matched with mutation-positive women who had not undergone the procedure in question (210 women for the analysis of endometrial cancer and 223 for the analysis of ovarian cancer). Women who had undergone prophylactic surgery and their matched controls were followed from the date of the surgery until the occurrence of cancer or until the data were censored at the time of the last follow-up visit. From the Departments of Gynecologic Oncology (K.M.S., P.T.S., K.G.W., S.G.B.-R., C.C.S., B.M.S., D.M.G., K.H.L.), Biostatistics and Applied Mathematics (M.F.M.), and Clinical Cancer Genetics (M.S.D.), the University of Texas M.D. Anderson Cancer Center, Houston; the Department of Preventive Medicine, Creighton University, Omaha, Nebr. (H.T.L., M.B.C.); and the Departments of Gynecologic Oncology (L.C., K.Y.Y., M.M.R.) and Medicine (P.G.C.), University of California at San Francisco, San Francisco. Address reprint requests to Dr. Lu at the Department of Gynecologic Oncology, University of Texas M.D. Anderson Cancer Center, P.O. Box , Unit 1362, Houston, TX , or at khlu@ mdanderson.org. N Engl J Med 2006;354: Copyright 2006 Massachusetts Medical Society. Results There were no occurrences of endometrial, ovarian, or primary peritoneal cancer among the women who had undergone prophylactic surgery. Endometrial cancer was diagnosed in 69 women in the control group (33 percent), for an incidence density of per woman-year, yielding a prevented fraction (the proportion of potential new cancers prevented) of 100 percent (95 percent confidence interval, 90 to 100 percent). Ovarian cancer was diagnosed in 12 women in the control group (5 percent), for an incidence density of per woman-year, yielding a prevented fraction of 100 percent (95 percent confidence interval, 62 to 100 percent). Conclusions These findings suggest that prophylactic hysterectomy with bilateral salpingo-oophorectomy is an effective strategy for preventing endometrial and ovarian cancer in women with the Lynch syndrome. n engl j med 354;3 january 19,

2 The Lynch syndrome (hereditary nonpolyposis colorectal cancer) is an autosomal dominant cancer-susceptibility syndrome caused by a germ-line mutation in one of the DNA-mismatch repair genes. 1-4 It is associated with an early onset of cancer and the development of multiple types of cancer, including cancer of the colon and rectum, endometrium, ovary, small bowel, ureter, and renal pelvis. The lifetime risk of endometrial cancer for women with the Lynch syndrome is 40 to 60 percent, which equals or exceeds their risk of colorectal cancer. In addition, they have a 10 to 12 percent lifetime risk of ovarian cancer. 5,6 Up to the present, data have been lacking on the basis of which to evaluate the efficacy of gynecologic surgery performed to reduce the risk of cancer in women with the Lynch syndrome. In 1997, the Cancer Genetics Studies Consortium reviewed the available evidence regarding the efficacy of prophylactic hysterectomy and bilateral salpingo-oophorectomy and published a consensus statement concluding that there was insufficient evidence for it to recommend whether or not women with the Lynch syndrome should have prophylactic surgery to reduce the risk of gynecologic cancer. 7 Despite the lack of evidence, several authors have suggested that hysterectomy with bilateral salpingo-oophorectomy is a reasonable preventive strategy for women with the Lynch syndrome, after they have completed childbearing We conducted a study to determine whether the risk of gynecologic cancers among women with the Lynch syndrome was reduced after hysterectomy and bilateral salpingo-oophorectomy. Methods Study patients Approval for this study, with a waiver of informed consent, was obtained from the institutional review board at each of the participating institutions. The records of patients enrolled in hereditary-cancer registries from 1973 to 2004 were reviewed. We identified 380 women with documented MLH1, MSH2, or MSH6 germ-line mutations from registries at Creighton University (284 women), the University of Texas M.D. Anderson Cancer Center (72 women), and the University of California at San Francisco (24 women). Women with genetic variants of unknown functional significance were excluded. The study was based on the 315 women (83 percent of the total) for whom follow-up information was available. Registry databases and patients medical records were reviewed to obtain information on demographic characteristics, genetic testing results, and vital status. Surgical information and occurrences of cancer were verified by reviews of medical records, operative notes, and pathology reports. Endometrial Cancer To determine whether prophylactic surgery reduced the risk of endometrial cancer, we performed a retrospective cohort analysis of women with germ-line mutations. In this analysis, we compared the outcome among those who had undergone hysterectomy either to prevent cancer or to treat benign conditions with the outcome among women who had not undergone hysterectomy (controls). We matched each woman who had undergone hysterectomy with one or more control women by a method similar to that used by Rebbeck et al. 11 Control women were of similar age to the women with whom they were matched (i.e., their dates of birth were within five years of each other), had been treated at the same institutions, and had been alive, with an intact uterus and no history of gynecologic cancer, at the time the women with whom they were matched underwent hysterectomy. Sixty-one wom en who had undergone hysterectomy, with or without salpingooophorectomy, were matched with 210 controls. Forty-four potential controls could not be matched with case women because their dates of birth did not fall within five years of that of any woman who had undergone hysterectomy, and therefore they were not included in the analysis. Ovarian Cancer We performed a similar analysis to evaluate the reduction in the risk of ovarian cancer after prophylactic surgery. Women who had undergone bilateral salpingo-oophorectomy for preventive reasons or to treat benign conditions were matched with one or more mutation-positive control women who were of similar age (date of birth within five years), had been treated at the same institution, had not undergone prophylactic bilateral salpingo-oophorectomy, and had been alive, with both ovaries intact and no history of gynecologic cancer, at the time the women with whom they 262 n engl j med 354;3 january 19, 2006

3 Prophylactic Surgery in Women with the Lynch Syndrome were matched underwent bilateral salpingo-oophorectomy. On the basis of these criteria, 47 women who had undergone prophylactic bilateral salpingo-oophorectomy were matched with 223 controls. Forty-five potential controls could not be matched with case women because their dates of birth did not fall within five years of that of any woman who had undergone bilateral salpingooophorectomy, and therefore they were not included in the analysis. Statistical Analysis The women who had undergone prophylactic surgery and the controls were followed from the date of the prophylactic surgery until the occurrence of endometrial, ovarian, or primary peritoneal cancer or until the observations were censored as of the date of death or the date of the last contact. The primary end point was the development of endometrial, ovarian, or primary peritoneal cancer. The incidence density 12 (the number of cancers divided by the number of years the women were at risk) was calculated for endometrial, ovarian, and primary peritoneal cancer in each group. The prevented fraction 12 ([incidence density for controls incidence density for women who underwent surgery] [incidence density for controls]), or the proportion of potential new cancers prevented, was estimated with the 95 percent confidence interval. The cumulative incidence of cancer was estimated by the method of Kaplan and Meier. 13 All analyses were performed with Stata (version 8.0) and S-PLUS 2000 software. Results Of the 315 women with germ-line mutations, 61 (19 percent) underwent gynecologic surgery for preventive reasons or to treat benign conditions. Forty-seven of these women underwent both hysterectomy and bilateral salpingo-oophorectomy, and 14 women underwent hysterectomy only. None of the women in our study underwent bilateral salpingo-oophorectomy without hysterectomy. Thirty-eight percent had genetic testing before undergoing prophylactic surgery. The characteristics of the entire study population are shown in Table 1. There were no significant differences among the participating institutions in the proportion of women who underwent prophylactic surgery. There were also no significant differences in the proportions of women with MLH1, MSH2, or MSH6 mutations between the group of women who underwent prophylactic surgery and the group who did not. Eighty-five percent of the women who had undergone prophylactic surgery, and 82 percent of the women who had not, were parous. Table 1. Characteristics of the 315 Women in the Study Population. Characteristic Prophylactic Surgery (N = 61)* number (percent) No Prophylactic Surgery (N = 254) P Value Institution where treated 0.66 Creighton University (N = 219) 43 (20) 176 (80) University of Texas M.D. 12 (17) 60 (83) Anderson Cancer Center (N = 72) University of California at 6 (25) 18 (75) San Francisco (N = 24) Parity 1 40 (85) 145 (82) 0.83 Mutation MLH1 29 (48) 108 (43) MSH2 31 (51) 143 (56) MSH6 0 3 (1) MLH1 and MSH2 1 (2) * Prophylactic surgery was defined as hysterectomy, with or without bilateral salpingo-oophorectomy, performed for the prevention of disease or for the treatment of a benign condition. Information on parity was available for 223 of 315 patients. n engl j med 354;3 january 19,

4 Endometrial Cancer Of the women who underwent prophylactic hysterectomy, none subsequently had endometrial cancer, as compared with 69 women (33 percent) in the control group (Table 2). The incidence density was per woman-year for the women who underwent prophylactic hysterectomy and per woman-year for the controls (P<0.001), yielding a prevented fraction of 100 percent (95 percent confidence interval, 90 to 100 percent). The cumulative incidence of endometrial cancer for each group is illustrated in Figure 1. The median age at prophylactic hysterectomy was 41 years (range, 20 to 63), and the median age at the diagnosis of endometrial cancer was 46 years (range, 30 to 69). Four endometrial cancers (6 percent) were diagnosed in women under 35 years of age. The women who underwent prophylactic hysterectomy were followed for an average of 13.3 years (range, 0.5 to 38.0) after surgery, and the controls were followed for an average of 7.4 years (range, 0.1 to 35.0) after the time of the matched woman s surgery. The distribution of patients according to the stage of endometrial cancer at diagnosis is shown in Table 2. Among women who did not undergo prophy- Table 2. Reduction in the Risk of Endometrial Cancer after Prophylactic Hysterectomy.* Variable Prophylactic Hysterectomy (N = 61) No Prophylactic Hysterectomy (N = 210) Cases of endometrial cancer no. (%) 0 69 (33) Age at surgery yr Median 41 NA Range NA Distribution of ages at surgery no. (%) 35 Yr 14 (23) NA Yr 15 (25) NA Yr 17 (28) NA >45 Yr 15 (25) NA Age at diagnosis of cancer yr Median NA 46 Range NA Distribution of ages at diagnosis no. (%) 35 Yr NA 4 (6) Yr NA 8 (12) Yr NA 22 (32) >45 Yr NA 35 (51) Cancer stage at diagnosis no. (%) I NA 48 (70) II NA 4 (6) III NA 6 (9) IV NA 0 (0) Unknown NA 11 (16) Follow-up yr Mean Range Total no. of woman-yr Incidence density (cases/woman-yr) * NA denotes not applicable. P< The prevented fraction is 100 percent (95 percent confidence interval, 90 to 100 percent). 264 n engl j med 354;3 january 19, 2006

5 Prophylactic Surgery in Women with the Lynch Syndrome lactic hysterectomy, endometrial cancer developed in 22 of those who had an MLH1 mutation (28 percent), 47 of those with an MSH2 mutation (37 percent), and none of those with an MSH6 mutation. The differences among these figures are not statistically significant. Ninety-two percent of the patients underwent genetic testing after receiving a diagnosis of endometrial cancer. Endometrial cancers were incidentally diagnosed in three women at the time of prophylactic hysterectomy. Two of the patients had stage I disease and one patient had stage II disease. They underwent surgery at 38, 58, and 48 years of age, respectively, and are currently alive, without any evidence of disease, 27, 2, and 4 years after surgery. At the time of the analysis, 25 women (9 percent) had died. Twenty-two of these women (10 percent) were from the control group and three (5 percent) had undergone prophylactic surgery. The causes of death among the women in the control group were endometrial cancer (three women), ovarian and colon cancer (one woman), colon cancer (seven women), other Lynch syndrome related cancers (four women), other cancers (two women), cardiac disease (one woman), and unknown (four women). The causes of death for the three women who underwent prophylactic surgery were colon cancer, brain cancer, and bladder cancer. Ovarian Cancer Of the 47 women who had undergone bilateral salpingo-oophorectomy at the time of their hysterectomy for cancer prevention or for benign conditions, none subsequently had ovarian cancer, as compared with 12 of the controls (5 percent) (Table 3). One of the women who had ovarian cancer had previously undergone hysterectomy for a benign condition without bilateral salpingooophorectomy. The incidence density was per woman-year for the women who had undergone surgery and per woman-year for the controls (P = 0.09). The prevented fraction was 100 percent (95 percent confidence interval, 62 to 100 percent). The cumulative incidence of ovarian cancer for each group is illustrated in Figure 2. The median age at prophylactic bilateral salpingo-oophorectomy was 41 years (range, 20 to 58), and the median age at the diagnosis of ovarian cancer was 42 years (range, 31 to 48). Two (17 percent) of the ovarian cancers were diagnosed in women before the age of 35. The average follow-up was 11.2 years (range, 0.5 to 38.0) after Incidence of Endometrial Cancer No. at Risk No hysterectomy Hysterectomy Hysterectomy Years surgery among women who had undergone prophylactic bilateral salpingo-oophorectomy and 10.6 years (range, 0.1 to 41.0) after the time of the matched woman s surgery among the control women. The distribution of women according to the stage of ovarian cancer at diagnosis is shown in Table 3. Among the women who did not undergo prophylactic bilateral salpingo-oophorectomy, ovarian cancer developed in five of those with an MLH1 mutation (6 percent), seven of those with an MSH2 mutation (5 percent), and none of those with an MSH6 mutation (P not significant). None of the women who underwent prophylactic hysterectomy with bilateral salpingo-oophorectomy subsequently had primary peritoneal cancer. Of the 12 cases of ovarian cancer, 3 (25 percent) were synchronous primary cancers of the ovary and endometrium according to the criteria of Scully et al. 14 No cases of ovarian cancer were incidentally diagnosed at the time of prophylactic bilateral salpingo-oophorectomy. Surgical Complications Surgical complications were noted in 1 of the 61 women who underwent prophylactic surgery (1.6 percent). The patient was a 27-year-old woman who had received a diagnosis of rectal carcinoma two years previously and had been treated by rectosigmoid resection with colostomy and creation of a Hartmann s pouch, followed by radiation No hysterectomy Figure 1. Cumulative Incidence of Endometrial Cancer among Women with the Lynch Syndrome Who Underwent Prophylactic Hysterectomy and Those Who Did Not n engl j med 354;3 january 19,

6 Table 3. Reduction in the Risk of Ovarian Cancer after Prophylactic Bilateral Salpingo-Oophorectomy.* Variable Prophylactic Bilateral Salpingo-oophorectomy (N = 47) No Prophylactic Bilateral Salpingo-oophorectomy (N = 223) Cases of ovarian cancer no. (%) 0 12 (5.5) Age at surgery yr Median 41 NA Range NA Distribution of ages at surgery no. (%) 35 Yr 10 (21) NA Yr 14 (30) NA Yr 10 (21) NA >45 Yr 13 (28) NA Age at diagnosis of cancer yr Median NA 42 Range NA Distribution of ages at diagnosis no. (%) 35 Yr NA 2 (17) Yr NA 3 (25) Yr NA 4 (33) >45 Yr NA 3 (25) Cancer stage at diagnosis no. (%) I NA 5 (42) II NA 3 (25) III NA 2 (17) IV NA 0 (0) Unknown NA 2 (17) Follow-up yr Mean Range Total no. of woman-yr Incidence density (cases/woman-yr) * NA denotes not applicable. P = The prevented fraction is 100 percent (95 percent confidence interval, 62 to 100 percent). therapy. At the time of prophylactic abdominal hysterectomy with bilateral salpingo-oophorectomy, a ureteral injury occurred and was repaired. The patient subsequently had a ureterovaginal fistula as well as a ureteroenteral fistula to the Hartmann s pouch and underwent a ureteroneocystostomy. She later had a rectovaginal fistula, which she decided not to have repaired. Metachronous Colorectal and Endometrial or Ovarian Cancer In our cohort, 107 women (34 percent) received a diagnosis of colorectal cancer. Forty-one patients had synchronous (3 patients) or metachronous (38 patients) colorectal cancer and endometrial or ovarian cancer (32 and 9 patients, respectively). The median age at the diagnosis of colorectal cancer was 47 years (range, 26 to 77). Five of the 41 women (12 percent) were 35 years old or younger, 6 (15 percent) were 36 to 40 years of age, 5 (12 percent) were 41 to 45 years of age, and 25 (61 percent) were over the age of 45. Twenty-one of these 41 women (51 percent) received a diagnosis of gynecologic cancer after receiving a diagnosis of and undergoing surgery for colo rectal cancer. The median time between the diagnoses of 266 n engl j med 354;3 january 19, 2006

7 Prophylactic Surgery in Women with the Lynch Syndrome colon cancer and gynecologic cancer was 5 years (range, 1 to 25). Discussion This study provides evidence of a benefit of prophylactic hysterectomy and bilateral salpingooophorectomy in preventing gynecologic cancers in women with the Lynch syndrome. In our cohort, there were no new cases of endometrial or ovarian cancer among the women who underwent prophylactic surgery. The reduction in the number of cancer cases was statistically significant for endometrial cancer but not for ovarian cancer; however, the power of the latter comparison was limited by the small number of ovarian cancers diagnosed in our cohort. The median age at diagnosis was 46 years for endometrial cancer and 42 years for ovarian cancer. These numbers are consistent with those in previous studies of women with the Lynch syndrome that have found a mean age at diagnosis of 48 to 49 years for endometrial cancer 15,16 and 42 years for ovarian cancer, 17 with the majority of cancers diagnosed in women after the age of 35. These findings support consideration of prophylactic hysterectomy and bilateral salpingo-oophorectomy in women with the Lynch syndrome after the age of 35, or once childbearing has been completed. There is currently limited information on the efficacy of surveillance in reducing the risk of endometrial and ovarian cancer in women with the Lynch syndrome. 18,19 Current screening guidelines for gynecologic cancer recommend annual pelvic examinations, transvaginal ultrasonography, endometrial biopsy, and measurements of serum CA-125 levels beginning at 25 to 35 years of age, 7 but controlled studies are lacking to support these methods in young premenopausal women. Information regarding screening for endometrial and ovarian cancer was not available for our cohort. Further research is needed to determine the efficacy of these screening methods in comparison with prophylactic surgery in reducing morbidity and mortality from endometrial and ovarian cancer in women with the Lynch syndrome. The disadvantages of prophylactic hysterectomy and bilateral salpingo-oophorectomy include surgical complications and premature menopause. The most common complications associated with hysterectomy and bilateral salpingo-oophorectomy are bleeding, infection, and injuries to the urinary tract and bowel. In our study, the surgical complication rate was 1.6 percent. This figure is consistent with previously published complication rates of 1 to 9 percent associated with hysterectomy and bilateral salpingo-oophorectomy for benign conditions In premenopausal women, bilateral salpingo-oophorectomy results in premature menopause, with attendant symptoms (including hot flashes, vaginal dryness, sexual dysfunction, and sleep disturbances) and an increased risk of osteoporosis Many of these conditions can usually be managed with hormonal or nonhormonal medications. 26 Information regarding these side effects was not available for our cohort. None of the women in our cohort received a diagnosis of primary peritoneal cancer after prophylactic bilateral salpingo-oophorectomy; however, our sample size and follow-up time were limited. Previous studies involving women with BRCA mutations have reported an incidence of primary peritoneal cancer after prophylactic bilateral salpingo-oophorectomy of 0.8 to 1.0 percent. 11,27 The risk of primary peritoneal cancer among women with the Lynch syndrome after prophylactic bilateral salpingo-oophorectomy remains uncertain. Three women who underwent prophylactic hysterectomy were found to have occult endometrial carcinomas at the time of surgery. This finding emphasizes the need to maintain a high index of suspicion during prophylactic surgery in women with the Lynch syndrome. 28 Preoperative assessment with endometrial biopsy, transvaginal ultrasonography, and measurement of CA-125 levels should be considered. The uterus and ovaries should be carefully assessed at the time of surgery; the pathologist should be advised of the high risk of endometrial and ovarian cancer, and the specimens should be carefully examined intraoperatively, with frozen sections obtained if indicated. The surgeon should be prepared to perform a complete staging operation, if necessary. In our cohort, 41 of 315 women (13 percent) received a diagnosis of synchronous or metachronous colorectal cancer and endometrial or ovarian cancer. Thirty-six of these women (88 percent) were older than 35 years at the time of their diagnosis of colorectal cancer. In 21 of these n engl j med 354;3 january 19,

8 Incidence of Ovarian Cancer No. at Risk No BSO BSO No BSO BSO Years Figure 2. Cumulative Incidence of Ovarian Cancer among Women with the Lynch Syndrome Who Underwent Prophylactic Bilateral Salpingo- Oophorectomy (BSO) and Those Who Did Not women, the gynecologic cancer was diagnosed after the woman had undergone treatment for colorectal cancer and could have been prevented if prophylactic hysterectomy and bilateral salpingo-oophorectomy had been performed at the time of surgery for colorectal cancer. Vasen et al. 15 evaluated the lifetime cancer risks associated with different gene mutations in 138 families in which the Lynch syndrome occurred. They found the risks of both endometrial cancer and ovarian cancer to be higher in MSH2 mutation carriers than in MLH1 mutation carriers, but the differences were not statistically significant. Similarly, we did not detect significant differences in the incidence of endometrial or ovarian cancer among women with MLH1, MSH2, and MSH6 mutations, but the power of this analysis was limited by our small sample size. A limitation of our study is that the data were collected retrospectively. Many of the women in our cohort underwent prophylactic surgery or received a diagnosis of cancer before they had undergone genetic testing. We did not have information on body-mass index or other risk factors for gynecologic cancers. In addition, we were unable to assess the effects of prophylactic surgery on survival and on deaths related to gynecologic cancer. Further studies with longer followup will be needed to assess the differences in survival between women who undergo prophylactic gynecologic surgery and those who do not. In summary, this study provides evidence of the efficacy of prophylactic surgery in preventing gynecologic cancers in women with the Lynch syndrome. Preoperative counseling should address the trade-offs between the reduction in the risk of cancer and the risks and side effects of surgery, as well as the uncertainties regarding surveillance of gynecologic cancer as an alternative management approach. Supported in part by a grant from the National Cancer Institute (N01-CN-05127). No potential conflict of interest relevant to this article was reported. We are indebted to Dr. Patrick M. Lynch, Dr. Russell R. Broaddus, and the Lynch syndrome registry at the University of Texas M.D. Anderson Cancer Center; to Mrs. Jane F. Lynch, Mr. William C. Dowart, and the Creighton University Lynch syndrome registry; and to Dr. Jonathan P. Terdiman, Ms. Amie M. Blanco, and the University of California at San Francisco Colorectal Cancer Prevention Program Familial Gastrointestinal Cancer Registry. References 1. Leach FS, Nicolaides NC, Papadopoulos N, et al. Mutations of a muts homolog in hereditary nonpolyposis colorectal cancer. Cell 1993;75: Fishel R, Lescoe MK, Rao MR, et al. The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. Cell 1993;75: [Erratum, Cell 1994;77:167.] 3. Papadopoulos N, Nicolaides NC, Wei YF, et al. Mutation of a mutl homolog in hereditary colon cancer. Science 1994;263: Kolodner RD, Tytell JD, Schmeits JL, et al. Germ-line msh6 mutations in colorectal cancer families. Cancer Res 1999; 59: Aarnio M, Sankila R, Pukkala E, et al. Cancer risk in mutation carriers of DNA- mismatch-repair genes. Int J Cancer 1999; 81: Dunlop MG, Farrington SM, Carothers AD, et al. Cancer risk associated with germline DNA mismatch repair gene mutations. Hum Mol Genet 1997;6: Burke W, Petersen G, Lynch P, et al. Recommendations for follow-up care of individuals with an inherited predisposition to cancer. I. Hereditary nonpolyposis colon cancer. JAMA 1997;277: Bertagnolli MM. Surgical prevention of cancer. J Clin Oncol 2005;23: Lynch HT, Watson P, Shaw TG, et al. Clinical impact of molecular genetic diagnosis, genetic counseling, and management of hereditary cancer. Part II: Hereditary nonpolyposis colorectal carcinoma as a model. Cancer 1999;86:Suppl 11: Lu KH, Dinh M, Kohlmann W, et al. Gynecologic cancer as a sentinel cancer for women with hereditary nonpolyposis colorectal cancer syndrome. Obstet Gynecol 2005;105: Rebbeck TR, Lynch HT, Neuhausen SL, et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 2002;346: Kleinbaum DG, Kupper LL, Morganstern H. Epidemiologic research. New York: Van Nostrand Reinhold, Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53: Tumors of the ovary, maldeveloped gonads, fallopian tube and broad ligament. In: Scully RE, Young RH, Clement PB. Atlas of tumor pathology. Bethesda, 268 n engl j med 354;3 january 19, 2006

9 Prophylactic Surgery in Women with the Lynch Syndrome Md.: Armed Forces Institute of Pathology, 1998: Vasen HF, Stormorken A, Menko FH, et al. MSH2 mutation carriers are at higher risk of cancer than MLH1 mutation carriers: a study of hereditary nonpolyposis colorectal cancer families. J Clin Oncol 2001;19: Boks DE, Trujillo AP, Voogd AC, Morreau H, Kenter GG, Vasen HF. Survival analysis of endometrial carcinoma associated with hereditary nonpolyposis colorectal cancer. Int J Cancer 2002;102: Watson P, Butzow R, Lynch HT, et al. The clinical features of ovarian cancer in hereditary nonpolyposis colorectal cancer. Gynecol Oncol 2001;82: Dove-Edwin I, Boks D, Goff S, et al. The outcome of endometrial carcinoma surveillance by ultrasound scan in women at risk of hereditary nonpolyposis colorectal carcinoma and familial colorectal carcinoma. Cancer 2002;94: Rijcken FE, Mourits MJ, Kleibeuker JH, Hollema H, van der Zee AG. Gynecologic screening in hereditary nonpolyposis colorectal cancer. Gynecol Oncol 2003;91: Kovac SR. Hysterectomy outcomes in patients with similar indications. Obstet Gynecol 2000;95: Weber AM, Lee JC. Use of alternative techniques of hysterectomy in Ohio, N Engl J Med 1996;335: [Erratum, N Engl J Med 1996;335:1406.] 22. Goodno JA Jr, Powers TW, Harris VD. Ureteral injury in gynecologic surgery: a ten-year review in a community hospital. Am J Obstet Gynecol 1995;172: Prior JC, Vigna YM, Wark JD, et al. Premenopausal ovariectomy-related bone loss: a randomized, double-blind, one-year trial of conjugated estrogen or medroxyprogesterone acetate. J Bone Miner Res 1997;12: Graziottin A, Basson R. Sexual dys- function in women with premature menopause. Menopause 2004;11: Menopause and the perimenopausal transition. In: Speroff L, Glass RH, Kase NG. Clinical gynecologic endocrinology and infertility. Baltimore: Lippincott Williams & Wilkins, 1999: Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women s Health Initiative randomized controlled trial. JAMA 2004; 291: Kauff ND, Satagopan JM, Robson ME, et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 2002;346: Chung L, Broaddus R, Crozier M, Luthraa R, Levenback C, Lu K. Unexpected endometrial cancer at prophylactic hysterectomy in a woman with hereditary nonpolyposis colon cancer. Obstet Gynecol 2003;102: Copyright 2006 Massachusetts Medical Society. FULL TEXT OF ALL JOURNAL ARTICLES ON THE WORLD WIDE WEB Access to the complete text of the Journal on the Internet is free to all subscribers. To use this Web site, subscribers should go to the Journal s home page ( and register by entering their names and subscriber numbers as they appear on their mailing labels. After this one-time registration, subscribers can use their passwords to log on for electronic access to the entire Journal from any computer that is connected to the Internet. Features include a library of all issues since January 1993 and abstracts since January 1975, a full-text search capacity, and a personal archive for saving articles and search results of interest. All articles can be printed in a format that is virtually identical to that of the typeset pages. Beginning six months after publication, the full text of all Original Articles and Special Articles is available free to nonsubscribers who have completed a brief registration. n engl j med 354;3 january 19,

Endometrial Cancer and Lynch Syndrome: Clinical and Pathologic Considerations

Endometrial Cancer and Lynch Syndrome: Clinical and Pathologic Considerations Lynch syndrome is associated with early onset of cancer, particularly colon and endometrial cancer, and thus warrants careful screening and prevention practices to decrease the likelihood of developing

More information

Policy #: 259 Latest Review Date: November 2009

Policy #: 259 Latest Review Date: November 2009 Name of Policy: Prophylactic Oophorectomy Policy #: 259 Latest Review Date: November 2009 Category: Surgery Policy Grade: Active Policy but no longer scheduled for regular literature reviews and updates.

More information

Gynecologic Cancers are many diseases. Gynecologic Cancers in the Age of Precision Medicine Advances in Internal Medicine. Speaker Disclosure:

Gynecologic Cancers are many diseases. Gynecologic Cancers in the Age of Precision Medicine Advances in Internal Medicine. Speaker Disclosure: Gynecologic Cancer Care in the Age of Precision Medicine Gynecologic Cancers in the Age of Precision Medicine Advances in Internal Medicine Lee-may Chen, MD Department of Obstetrics, Gynecology & Reproductive

More information

Content. Diagnostic approach and clinical management of Lynch Syndrome: guidelines. Terminology. Identification of Lynch Syndrome

Content. Diagnostic approach and clinical management of Lynch Syndrome: guidelines. Terminology. Identification of Lynch Syndrome of Lynch Syndrome: guidelines 17/03/2009 Content Terminology Lynch Syndrome Presumed Lynch Syndrome Familial Colorectal Cancer Identification of Lynch Syndrome Amsterdam II criteria Revised Bethesda Guidelines

More information

Lynch Syndrome. Angie Strang, PGY2

Lynch Syndrome. Angie Strang, PGY2 Lynch Syndrome Angie Strang, PGY2 Background Previously hereditary nonpolyposis colorectal cancer Autosomal dominant inherited cancer susceptibility syndrome Caused by defects in the mismatch repair system

More information

Gynecologic Cancers are many diseases. Speaker Disclosure: Gynecologic Cancer Care in the Age of Precision Medicine. Controversies in Women s Health

Gynecologic Cancers are many diseases. Speaker Disclosure: Gynecologic Cancer Care in the Age of Precision Medicine. Controversies in Women s Health Gynecologic Cancer Care in the Age of Precision Medicine Gynecologic Cancers in the Age of Precision Medicine Controversies in Women s Health Lee-may Chen, MD Department of Obstetrics, Gynecology & Reproductive

More information

Tumori eredofamiliari: sorveglianza di donne ad alto rischio

Tumori eredofamiliari: sorveglianza di donne ad alto rischio Tumori eredofamiliari: sorveglianza di donne ad alto rischio 14/01/2018 Dott Matteo Generali AUSL Modena Carpi U.O. Ostetricia e Ginecologia Screening for gynaecologic cancer in genetically predisposed

More information

6 Week Course Agenda. Today s Agenda. Ovarian Cancer: Risk Factors. Winning the War 11/30/2016 on Women s Cancer Gynecologic Cancer Prevention

6 Week Course Agenda. Today s Agenda. Ovarian Cancer: Risk Factors. Winning the War 11/30/2016 on Women s Cancer Gynecologic Cancer Prevention 6 Week Course Agenda Winning the War 11/30/2016 on Women s Cancer Gynecologic Cancer Prevention Lee-may Chen, MD Director, Division of Gynecologic Oncology Professor Department of Obstetrics, Gynecology

More information

The Whys OAP Annual Meeting CCO Symposium September 20. Immunohistochemical Assessment Dr. Terence Colgan Mount Sinai Hospital, Toronto

The Whys OAP Annual Meeting CCO Symposium September 20. Immunohistochemical Assessment Dr. Terence Colgan Mount Sinai Hospital, Toronto Immunohistochemical Assessment of Mismatch Repair Proteins in Endometrial Cancer: The Whys and How Terence J. Colgan, MD Head of Gynaecological Pathology, Mount Sinai Hospital, University of Toronto, Toronto.

More information

BSO, HRT, and ERT. No relevant financial disclosures

BSO, HRT, and ERT. No relevant financial disclosures BSO, HRT, and ERT Jubilee Brown, MD Professor & Associate Director, Gynecologic Oncology Levine Cancer Institute at the Carolinas HealthCare System Charlotte, North Carolina No relevant financial disclosures

More information

Review Article Clinicopathological Features and Management of Cancers in Lynch Syndrome

Review Article Clinicopathological Features and Management of Cancers in Lynch Syndrome Pathology Research International Volume 2012, Article ID 350309, 6 pages doi:10.1155/2012/350309 Review Article Clinicopathological Features and Management of Cancers in Lynch Syndrome Markku Aarnio Department

More information

Primary Care Approach to Genetic Cancer Syndromes

Primary Care Approach to Genetic Cancer Syndromes Primary Care Approach to Genetic Cancer Syndromes Jason M. Goldman, MD, FACP FAU School of Medicine Syndromes Hereditary Breast and Ovarian Cancer (HBOC) Hereditary Nonpolyposis Colorectal Cancer (HNPCC)

More information

Guidelines on Genetic Evaluation and Management of Lynch Syndrome: A Consensus Statement by the US Multi-Society Task Force on Colorectal Cancer

Guidelines on Genetic Evaluation and Management of Lynch Syndrome: A Consensus Statement by the US Multi-Society Task Force on Colorectal Cancer s on Genetic Evaluation and Management of Lynch Syndrome: A Consensus Statement by the US Multi-Society Task Force on Colorectal Cancer Francis M. Giardiello, MD, 1 John I. Allen, 2 Jennifer E. Axilbund,

More information

MSH6 gene. Associated Syndrome Name: Lynch syndrome/hereditary NonPolyposis Colorectal Cancer (HNPCC) MSH6 Summary Cancer Risk Table

MSH6 gene. Associated Syndrome Name: Lynch syndrome/hereditary NonPolyposis Colorectal Cancer (HNPCC) MSH6 Summary Cancer Risk Table MSH6 gene Associated Syndrome Name: Lynch syndrome/hereditary NonPolyposis Colorectal Cancer (HNPCC) MSH6 Summary Cancer Risk Table CANCER Colorectal GENETIC CANCER RISK High Risk Endometrial High Risk

More information

Risk of Colorectal Cancer (CRC) Hereditary Syndromes in GI Cancer GENETIC MALPRACTICE

Risk of Colorectal Cancer (CRC) Hereditary Syndromes in GI Cancer GENETIC MALPRACTICE Identifying the Patient at Risk for an Inherited Syndrome Sapna Syngal, MD, MPH, FACG Director, Gastroenterology Director, Familial GI Program Dana-Farber/Brigham and Women s Cancer Center Associate Professor

More information

Surgery to Reduce the Risk of Ovarian Cancer. Information for Women at Increased Risk

Surgery to Reduce the Risk of Ovarian Cancer. Information for Women at Increased Risk Surgery to Reduce the Risk of Ovarian Cancer Information for Women at Increased Risk Centre for Genetics Education NSW Health 2017 The Centre for Genetics Education NSW Health Level 5 2C Herbert St St

More information

What is the gynecologist s role in the care of BRCA previvors?

What is the gynecologist s role in the care of BRCA previvors? What is the gynecologist s role in the care of BRCA previvors? Here, your patient s options for surgery and your best options for her follow-up care and ongoing surveillance OBG Manag. Sept 2013;25(9):10-14.

More information

Ovarian Cancer Causes, Risk Factors, and Prevention

Ovarian Cancer Causes, Risk Factors, and Prevention Ovarian Cancer Causes, Risk Factors, and Prevention Risk Factors A risk factor is anything that affects your chance of getting a disease such as cancer. Learn more about the risk factors for ovarian cancer.

More information

Result Navigator Positive Test Result: MSH6

Result Navigator Positive Test Result: MSH6 Result Navigator Positive Test Result: MSH6 Positive test results identify a change, or misspelling, of DNA that is known or predicted to cause an increased risk for cancer. DNA is the blueprint of life

More information

MLH1 gene. Associated Syndrome Name: Lynch syndrome/hereditary NonPolyposis Colorectal Cancer (HNPCC) MLH1 Summary Cancer Risk Table

MLH1 gene. Associated Syndrome Name: Lynch syndrome/hereditary NonPolyposis Colorectal Cancer (HNPCC) MLH1 Summary Cancer Risk Table MLH1 gene Associated Syndrome Name: Lynch syndrome/hereditary NonPolyposis Cancer (HNPCC) MLH1 Summary Cancer Risk Table CANCER GENETIC CANCER RISK Endometrial Other MLH1 gene Overview Lynch syndrome 1,

More information

How common are mutations in the MSH2 gene? 1. Mutations that cause Lynch syndrome are rare found in approximately 1 in 370 individuals.

How common are mutations in the MSH2 gene? 1. Mutations that cause Lynch syndrome are rare found in approximately 1 in 370 individuals. The gene is a tumor suppressor gene. Tumor suppressor genes slow down cell division, repair DNA mistakes, or tell cells when to die. When they don't work properly, cells can grow out of control, which

More information

RESEARCH COMMUNICATION

RESEARCH COMMUNICATION RESEARCH COMMUNICATION Clinicopathologic Analysis of Women with Synchronous Primary Carcinomas of the Endometrium and Ovary: 10- Year Experience from Chiang Mai University Hospital Jiraprapa Natee 1 *,

More information

Understanding and Managing Lynch Syndrome

Understanding and Managing Lynch Syndrome Understanding and Managing Lynch Syndrome Princess Margaret For women who may have Lynch syndrome and their family members Please visit the UHN Patient Education website for more health information: www.uhnpatienteducation.ca

More information

Mr Chris Wakeman. General Surgeon University of Otago, Christchurch. 12:15-12:40 Management of Colorectal Cancer

Mr Chris Wakeman. General Surgeon University of Otago, Christchurch. 12:15-12:40 Management of Colorectal Cancer Mr Chris Wakeman General Surgeon University of Otago, Christchurch 12:15-12:40 Management of Colorectal Cancer Bowel cancer Chris Wakeman Colorectal Surgeon Christchurch Sam Simon (Simpsons) Elizabeth

More information

Genetic Counseling: Dealing with Uncertainty. Kathy J. Helzlsouer, MD, MHS Epidemiology and Genomics Research Program, DCCPS, NCI August 17, 2017

Genetic Counseling: Dealing with Uncertainty. Kathy J. Helzlsouer, MD, MHS Epidemiology and Genomics Research Program, DCCPS, NCI August 17, 2017 Genetic Counseling: Dealing with Uncertainty Kathy J. Helzlsouer, MD, MHS Epidemiology and Genomics Research Program, DCCPS, NCI August 17, 2017 2 Multiple Paths to Genetic Counseling/Testing Family history

More information

PMS2 gene. Associated Syndrome Name: Lynch syndrome/hereditary NonPolyposis Colorectal Cancer (HNPCC) PMS2 Summary Cancer Risk Table

PMS2 gene. Associated Syndrome Name: Lynch syndrome/hereditary NonPolyposis Colorectal Cancer (HNPCC) PMS2 Summary Cancer Risk Table PMS2 gene Associated Syndrome Name: Lynch syndrome/hereditary NonPolyposis Colorectal Cancer (HNPCC) PMS2 Summary Cancer Risk Table CANCER Colorectal GENETIC CANCER RISK High Risk Endometrial High Risk

More information

FAQ-Protocol 3. BRCA mutation carrier guidelines Frequently asked questions

FAQ-Protocol 3. BRCA mutation carrier guidelines Frequently asked questions ULast updated: 09/02/2015 Protocol 3 BRCA mutation carrier guidelines Frequently asked questions UQ: How accurate are the remaining lifetime and 5 year breast cancer risks in the table? These figures are

More information

Practice of Medicine-1 Ovarian Cancer Clinical Correlation

Practice of Medicine-1 Ovarian Cancer Clinical Correlation Practice of Medicine-1 Ovarian Cancer Clinical Correlation Amir A. Jazaeri, M.D. Assistant Professor, Division of Gynecologic Oncology American Cancer Society Female Cancers 2000 Statistics Reprinted by

More information

Inherited Ovarian Cancer Diagnosis and Prevention

Inherited Ovarian Cancer Diagnosis and Prevention Inherited Ovarian Cancer Diagnosis and Prevention Dr. Jacob Korach - Deputy director Gynecologic Oncology (past chair - Israeli Society of Gynecologic Oncology) Prof. Eitan Friedman - Head, Oncogenetics

More information

Genetic Determinants, Risk Assessment and Management

Genetic Determinants, Risk Assessment and Management Genetic Determinants, Risk Assessment and Management Rachel Rando, MS, CGC Genetic Counselor Hunterdon Regional Cancer Center Flemington, NJ I have no disclosures. Acknowledgements: Staff of Hunterdon

More information

Partners: Introductions: Dr. Carolyn Johnston Deanna Cosens & Ann Garvin. Ovarian Cancer and Primary Care July 16, :00 9:00am EST 7/16/2014

Partners: Introductions: Dr. Carolyn Johnston Deanna Cosens & Ann Garvin. Ovarian Cancer and Primary Care July 16, :00 9:00am EST 7/16/2014 Welcome To The Webinar Technical Support Ovarian Cancer and Primary Care July 16, 2014 8:00 9:00am EST In order to hear the presentation please call 1 (626) 544-0058, access code 167-314-644, followed

More information

Christine Garcia, MD 1, Liisa Lyon, MS 2, Ramey D. Littell, MD 1 and C. Bethan Powell, MD 1

Christine Garcia, MD 1, Liisa Lyon, MS 2, Ramey D. Littell, MD 1 and C. Bethan Powell, MD 1 American College of Medical Genetics and Genomics Comparison of risk management strategies between women positive for a BRCA variant of unknown significance and women with known BRCA deleterious mutations

More information

--- or not, and do we need to come up with newer strategies for ovarian cancer screening.

--- or not, and do we need to come up with newer strategies for ovarian cancer screening. My name is Dr. Karen Lu and I am a Professor of Gynecologic Oncology at the University of Texas MD Anderson Cancer Center. I also serve as Co-Medical Director for Clinical Cancer Genetics. I m going to

More information

Clinical significance of mismatch repair genes immunohistochemical expression of complex endometrial hyperplasia

Clinical significance of mismatch repair genes immunohistochemical expression of complex endometrial hyperplasia Original Article Obstet Gynecol Sci 2015;58(2):106-111 http://dx.doi.org/10.5468/ogs.2015.58.2.106 pissn 2287-8572 eissn 2287-8580 Clinical significance of mismatch repair genes immunohistochemical expression

More information

FACT SHEET 49. What is meant by a family history of bowel cancer? What is bowel cancer? What causes bowel cancer?

FACT SHEET 49. What is meant by a family history of bowel cancer? What is bowel cancer? What causes bowel cancer? Important points The most important factors that can influence an individual s chance of developing bowel cancer are getting older and having a family history of bowel cancer A family history of bowel

More information

So, now, that we have reviewed some basics of cancer genetics I will provide an overview of some common syndromes.

So, now, that we have reviewed some basics of cancer genetics I will provide an overview of some common syndromes. Hello. My name is Maureen Mork and I m a Certified Genetic Counselor in the Clinical Cancer Genetics Program at The University of Texas MD Anderson Cancer Center. I ll be lecturing today on the Cancer

More information

Ask the Experts Obstetrics & Gynecology

Ask the Experts Obstetrics & Gynecology 1 Management of the Adnexal Mass James H. Liu, MD, and Kristine M. Zanotti, MD June 2011 Volume 117 Issue 6 Pages 1413 28 Click Here to Read the Full Article Questions written by: Rini Banerjee Ratan,

More information

Review Article Relationship between DNA Mismatch Repair Deficiency and Endometrial Cancer

Review Article Relationship between DNA Mismatch Repair Deficiency and Endometrial Cancer SAGE-Hindawi Access to Research Molecular Biology International Volume 2011, Article ID 256063, 6 pages doi:10.4061/2011/256063 Review Article Relationship between DNA Mismatch Repair Deficiency and Kenta

More information

Page 1 of 8 TABLE OF CONTENTS

Page 1 of 8 TABLE OF CONTENTS Page 1 of 8 TABLE OF CONTENTS Patient Evaluation and Recommendation..Page 2 Testing and Follow-up..Page 3 Genetic Counseling Referral Criteria.....Page 4-5 Patient Education..Page 6 Suggested Readings...Page

More information

Case Presentation Diana Lim, MBBS, FRCPA, FRCPath Senior Consultant Department of Pathology, National University Health System, Singapore Assistant Pr

Case Presentation Diana Lim, MBBS, FRCPA, FRCPath Senior Consultant Department of Pathology, National University Health System, Singapore Assistant Pr Case Presentation Diana Lim, MBBS, FRCPA, FRCPath Senior Consultant Department of Pathology, National University Health System, Singapore Assistant Professor Yong Loo Lin School of Medicine, National University

More information

The New England Journal of Medicine PROPHYLACTIC OOPHORECTOMY IN CARRIERS OF BRCA1 OR BRCA2 MUTATIONS. Study Participants

The New England Journal of Medicine PROPHYLACTIC OOPHORECTOMY IN CARRIERS OF BRCA1 OR BRCA2 MUTATIONS. Study Participants PROPHYLACTIC OOPHORECTOMY IN CARRIERS OF BRCA1 OR BRCA2 MUTATIONS TIMOTHY R. REBBECK, PH.D., HENRY T. LYNCH, M.D., SUSAN L. NEUHAUSEN, PH.D., STEVEN A. ROD, M.D., LAURA VAN T VEER, PH.D., JUDY E. GARBER,

More information

Utilization of BRCA Testing. Breast and Ovarian Cancer in Texas

Utilization of BRCA Testing. Breast and Ovarian Cancer in Texas Utilization of BRCA Testing in Older Ode Women with Breast and Ovarian Cancer in Texas Ana M. Rodriguez, MD Assistant Professor Department of Obstetrics and Gynecology University of Texas Medical Branch

More information

Screening and prevention of ovarian cancer

Screening and prevention of ovarian cancer Chapter 2 Screening and prevention of ovarian cancer Prevention of ovarian carcinoma Oral contraceptive pills Use of oral contraceptive pills (OCPs) has been associated with a significant reduction in

More information

Shina Oranratanaphan, Tarinee Manchana*, Nakarin Sirisabya

Shina Oranratanaphan, Tarinee Manchana*, Nakarin Sirisabya Comparison of Synchronous Endometrial and Ovarian Cancers versus Primary with Metastasis RESEARCH COMMUNICATION Clinicopathologic Variables and Survival Comparison of Patients with Synchronous Endometrial

More information

Protocols 9-12 MMR mutation carrier guidelines Frequently asked questions

Protocols 9-12 MMR mutation carrier guidelines Frequently asked questions Protocols 9-12 MMR mutation carrier guidelines Frequently asked questions Last updated: 10/02/2015 Q: Where have the general population cancer risks been taken from? The risk figures for the general population

More information

Importance of Family History in Gynecologic Cancer Prevention. Objectives. Genetic Counselors. Angela Thompson, MS, CGC

Importance of Family History in Gynecologic Cancer Prevention. Objectives. Genetic Counselors. Angela Thompson, MS, CGC Importance of Family History in Gynecologic Cancer Prevention Angela Thompson, MS, CGC Genetic Counselor Froedtert & The Medical College of Wisconsin Objectives Introduce role of genetic counselor Discuss

More information

Is It Time To Implement Ovarian Cancer Screening?

Is It Time To Implement Ovarian Cancer Screening? Is It Time To Implement Ovarian Cancer Screening? Prof Dr Samet Topuz Istanbul Medıcal Faculty Department Of Obstetrics and Gynecology ESGO Prevention in Gynaecological Malignancies September 08 2016 Antalya

More information

Long-Term Health Outcomes of Surgical Menopause

Long-Term Health Outcomes of Surgical Menopause Long-Term Health Outcomes of Surgical Menopause Vanessa Jacoby, MD, MAS Associate Professor Obstetrics, Gynecology, and Reproductive Sciences University of California, San Francisco None Disclosures Overview

More information

COLON CANCER GENETICS (FOR SURGEONS) Mark W. Arnold MD Chief, Division of Colon and Rectal Surgery Professor of Surgery The Ohio State University

COLON CANCER GENETICS (FOR SURGEONS) Mark W. Arnold MD Chief, Division of Colon and Rectal Surgery Professor of Surgery The Ohio State University COLON CANCER GENETICS (FOR SURGEONS) Mark W. Arnold MD Chief, Division of Colon and Rectal Surgery Professor of Surgery The Ohio State University 1. I am a surgeon; of course I have nothing to disclose.

More information

So, Who are the appropriate individuals that should consider genetic counseling and genetic testing?

So, Who are the appropriate individuals that should consider genetic counseling and genetic testing? Hello, I m Banu Arun, Professor of Breast Medical Oncology and Co-Director of Clinical Cancer Genetics at the University of Texas MD Anderson Cancer Center. Today I will be discussing with you Hereditary

More information

Oncologist. The. Review and Commentary. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate

Oncologist. The. Review and Commentary. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate The Oncologist Review and Commentary Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate M. STEVEN PIVER Department of Gynecologic Oncology, Gilda

More information

Inherited Breast and Ovarian Cancer: 20 Years of Progress and Future Directions

Inherited Breast and Ovarian Cancer: 20 Years of Progress and Future Directions Inherited Breast and Ovarian Cancer: 20 Years of Progress and Future Directions Noah D. Kauff, MD, FACOG Director, Clinical Cancer Genetics Duke Cancer Institute / Duke University Health System Disclosures

More information

X-Plain Ovarian Cancer Reference Summary

X-Plain Ovarian Cancer Reference Summary X-Plain Ovarian Cancer Reference Summary Introduction Ovarian cancer is fairly rare. Ovarian cancer usually occurs in women who are over 50 years old and it may sometimes be hereditary. This reference

More information

POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT VARIATIONS DISCLAIMER CODING INFORMATION REFERENCES POLICY HISTORY

POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT VARIATIONS DISCLAIMER CODING INFORMATION REFERENCES POLICY HISTORY Original Issue Date (Created): October 1, 2014 Most Recent Review Date (Revised): May 20, 2014 Effective Date: October 1, 2014 POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT

More information

Prevention, Diagnosis and Treatment of Gynecologic Cancers

Prevention, Diagnosis and Treatment of Gynecologic Cancers Prevention, Diagnosis and Treatment of Gynecologic Cancers Jubilee Brown MD and Pamela T. Soliman MD, MPH Department of Gynecologic Oncology and Reproductive Medicine University of Texas MD Anderson Cancer

More information

SCREENING FOR OVARIAN CANCER DR MACİT ARVAS

SCREENING FOR OVARIAN CANCER DR MACİT ARVAS SCREENING FOR OVARIAN CANCER DR MACİT ARVAS Ovarian cancer is the leading cause of death from gynecologic malignancy In 2008, ovarian cancer was the seventh common cancer in women worldwide There were

More information

What You Need to Know About Ovarian Cancer

What You Need to Know About Ovarian Cancer What You Need to Know About Ovarian Cancer About Us The Rhode Island Ovarian Cancer Alliance (RIOCA) was formed in honor and memory of Jessica Morris. Jessica was diagnosed with Stage IIIC Ovarian Cancer

More information

Key Recommendations. Gynecologic management of women with inherited risk of gynecologic cancer

Key Recommendations. Gynecologic management of women with inherited risk of gynecologic cancer Gynecologic management of women with inherited risk of gynecologic cancer C. Bethan Powell MD Kaiser Permanente Northern California Gynecologic Oncology Program Lead, Kaiser Permanente Northern California

More information

Menopause and Cancer risk; What to do overcome the risks? Fatih DURMUŞOĞLU,M.D

Menopause and Cancer risk; What to do overcome the risks? Fatih DURMUŞOĞLU,M.D Menopause and Cancer risk; What to do overcome the risks? Fatih DURMUŞOĞLU,M.D Menopause and Cancer How does menopause affect a woman s cancer risk? Ø Menopause does not cause cancer.but risk of developing

More information

LYNCH-SYNDROME RELATED GYNECOLOGIC PATHOLOGY MARIA LUISA CARCANGIU M.D.

LYNCH-SYNDROME RELATED GYNECOLOGIC PATHOLOGY MARIA LUISA CARCANGIU M.D. LYNCH-SYNDROME RELATED GYNECOLOGIC PATHOLOGY MARIA LUISA CARCANGIU M.D. Aldred Scott Warthin Warthin A. Heredity with reference to carcinoma. Arch Intern Med. 1913; 4:681 696 History 1913- Michigan pathologist

More information

Policy Specific Section: Medical Necessity and Investigational / Experimental. October 14, 1998 March 28, 2014

Policy Specific Section: Medical Necessity and Investigational / Experimental. October 14, 1998 March 28, 2014 Medical Policy Genetic Testing for Colorectal Cancer Type: Medical Necessity and Investigational / Experimental Policy Specific Section: Laboratory/Pathology Original Policy Date: Effective Date: October

More information

BRCA2 gene. Associated Syndrome Name: Hereditary Breast and Ovarian Cancer syndrome (HBOC) BRCA2 Summary Cancer Risk Table. BRCA2 gene Overview

BRCA2 gene. Associated Syndrome Name: Hereditary Breast and Ovarian Cancer syndrome (HBOC) BRCA2 Summary Cancer Risk Table. BRCA2 gene Overview BRCA gene Associated Syndrome Name: Hereditary Breast and Cancer syndrome (HBOC) BRCA Summary Cancer Risk Table Male Breast GENETIC RISK Female Breast Elevated Risk Elevated Risk BRCA gene Overview Hereditary

More information

ORIGINAL INVESTIGATION. Association Between Colorectal Cancer and Urologic Cancers

ORIGINAL INVESTIGATION. Association Between Colorectal Cancer and Urologic Cancers ORIGINAL INVESTIGATION Association Between Colorectal and Urologic s Audrey H. Calderwood, MD; Dezheng Huo, hd; David T. Rubin, MD Background: Different types of urologic cancers have been associated with

More information

Guidelines for the assessment of mismatch repair (MMR) status in Colorectal Cancer

Guidelines for the assessment of mismatch repair (MMR) status in Colorectal Cancer Guidelines for the assessment of mismatch repair (MMR) status in Colorectal Cancer Start date: May 2015 Review date: April 2018 1 Background Mismatch repair (MMR) deficiency is seen in approximately 15%

More information

Incidence and Clinical Characteristics of Colonic and Extra Colonic Lynch Syndrome Manifestations in Uruguayan Mismatch Repair Carriers

Incidence and Clinical Characteristics of Colonic and Extra Colonic Lynch Syndrome Manifestations in Uruguayan Mismatch Repair Carriers Research Article imedpub Journals http://www.imedpub.com/ Colorectal Cancer: Open Access ISSN 47-9943 07 Vol.3 No.:6 DOI: 0.767/47-9943.00036 Incidence and Clinical Characteristics of Colonic and Extra

More information

EDUCATIONAL COMMENTARY CA 125. Learning Outcomes

EDUCATIONAL COMMENTARY CA 125. Learning Outcomes EDUCATIONAL COMMENTARY CA 125 Learning Outcomes Upon completion of this exercise, participants will be able to: discuss the use of CA 125 levels in monitoring patients undergoing treatment for ovarian

More information

Advice about familial aspects of breast cancer and epithelial ovarian cancer

Advice about familial aspects of breast cancer and epithelial ovarian cancer Advice about familial aspects of breast cancer and epithelial ovarian cancer a guide for health professionals FEBRUARY 2006 These guidelines contain three parts: 1. Information for health professionals

More information

Measure Description. Denominator Statement

Measure Description. Denominator Statement CMS ID/CMS QCDR ID: CAP 18 Title: Mismatch Repair (MMR) or Microsatellite Instability (MSI) Biomarker Testing to Inform Clinical Management and Treatment Decisions in Patients with Primary or Metastatic

More information

Genetic Testing for Lynch Syndrome

Genetic Testing for Lynch Syndrome Genetic Testing for Lynch Syndrome MP9487 Covered Service: Prior Authorization Required: Additional Information: Yes when meets criteria below Yes-as shown below Pre and post-test genetic counseling is

More information

What I wish I d known before surgery: BRCA carriers perspectives after bilateral salipingo-oophorectomy

What I wish I d known before surgery: BRCA carriers perspectives after bilateral salipingo-oophorectomy Familial Cancer (2011) 10:79 85 DOI 10.1007/s10689-010-9384-z What I wish I d known before surgery: BRCA carriers perspectives after bilateral salipingo-oophorectomy Danielle Campfield Bonadies Anne Moyer

More information

A Patient s Guide to risk assessment. Hereditary Colorectal Cancer

A Patient s Guide to risk assessment. Hereditary Colorectal Cancer A Patient s Guide to risk assessment Hereditary Colorectal Cancer Hereditary Cancer Testing: Is it Right for You? Overview of Syndromes This workbook is designed to help you decide if hereditary cancer

More information

Breast Cancer Prevention Studies. Key Points. Breast cancer prevention studies are clinical trials (research studies conducted with

Breast Cancer Prevention Studies. Key Points. Breast cancer prevention studies are clinical trials (research studies conducted with CANCER FACTS N a t i o n a l C a n c e r I n s t i t u t e N a t i o n a l I n s t i t u t e s o f H e a l t h D e p a r t m e n t o f H e a l t h a n d H u m a n S e r v i c e s Breast Cancer Prevention

More information

Hereditary Non Polyposis Colorectal Cancer(HNPCC) From clinic to genetics

Hereditary Non Polyposis Colorectal Cancer(HNPCC) From clinic to genetics From clinic to genetics Question 1) Clinical pattern of inheritance of the HNPCC-Syndrome? Question 1) Clinical pattern of inheritance of the HNPCC-Syndrome? Autosomal dominant Question 2) Incidence of

More information

Learning Objectives. Peri menopause. Menopause Overview. Recommendation grading categories

Learning Objectives. Peri menopause. Menopause Overview. Recommendation grading categories Learning Objectives Identify common symptoms of the menopause transition Understand the risks and benefits of hormone replacement therapy (HRT) Be able to choose an appropriate hormone replacement regimen

More information

What is ovarian cancer?

What is ovarian cancer? What is ovarian cancer? Ovarian cancer is a type of cancer that forms in tissues of the ovary. Most ovarian cancers are either ovarian epithelial cancers (cancer that begins in the cells on the surface

More information

Factors Associated with Early Versus Late Development of Breast and Ovarian Cancer in BRCA1 and BRCA2 Positive Women

Factors Associated with Early Versus Late Development of Breast and Ovarian Cancer in BRCA1 and BRCA2 Positive Women Texas Medical Center Library DigitalCommons@The Texas Medical Center UT GSBS Dissertations and Theses (Open Access) Graduate School of Biomedical Sciences 5-2010 Factors Associated with Early Versus Late

More information

Hereditary Cancer Update Strengthening Linkages Workshop April 22, 2017

Hereditary Cancer Update Strengthening Linkages Workshop April 22, 2017 Hereditary Cancer Update Strengthening Linkages Workshop April 22, 2017 Renée Perrier, MD MSc FRCPC Clinical Assistant Professor University of Calgary, Department of Medical Genetics Medical Director,

More information

We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors

We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 3,350 108,000 1.7 M Open access books available International authors and editors Downloads Our

More information

The risk of ovarian cancer after breast cancer in BRCA1 and BRCA2 carriers

The risk of ovarian cancer after breast cancer in BRCA1 and BRCA2 carriers Gynecologic Oncology 96 (2005) 222 226 www.elsevier.com/locate/ygyno The risk of ovarian cancer after breast cancer in BRCA1 and BRCA2 carriers Kelly A. Metcalfe a,b, *, Henry T. Lynch c, Parviz Ghadirian

More information

J Clin Oncol 22: by American Society of Clinical Oncology INTRODUCTION. Women who carry a germline mutation in

J Clin Oncol 22: by American Society of Clinical Oncology INTRODUCTION. Women who carry a germline mutation in VOLUME 22 NUMBER 12 JUNE 15 2004 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Contralateral Breast Cancer in BRCA1 and BRCA2 Mutation Carriers Kelly Metcalfe, Henry T. Lynch, Parviz Ghadirian,

More information

Research. Breast cancer represents a major

Research. Breast cancer represents a major Research GENERAL GYNECOLOGY Gynecologic conditions in participants in the NSABP breast cancer prevention study of tamoxifen and raloxifene (STAR) Carolyn D. Runowicz, MD; Joseph P. Costantino, DrPH; D.

More information

BRCA genes and inherited breast and ovarian cancer. Information for patients

BRCA genes and inherited breast and ovarian cancer. Information for patients BRCA genes and inherited breast and ovarian cancer Information for patients This booklet has been written for people who have a personal or family history of breast and/or ovarian cancer that could be

More information

Familial Cancer Clinic Information Sheet. Surgery to prevent endometrial and ovarian cancer. in women with Lynch Syndrome

Familial Cancer Clinic Information Sheet. Surgery to prevent endometrial and ovarian cancer. in women with Lynch Syndrome Familial Cancer Clinic Institute for Women s Health 1 st Floor, Maple House 124 Tottenham Court Road W1T 7DN Telephone: 020 7380 6912 Fax: 020 7380 6929 Email: michelle.johnson@ucl.ac.uk Familial Cancer

More information

Lynch Syndrome (HNPCC) and MYH-Associated Polyposis (MAP)

Lynch Syndrome (HNPCC) and MYH-Associated Polyposis (MAP) Lynch Syndrome (HNPCC) and MYH-Associated Polyposis (MAP) A Patient s Guide to risk assessment Hereditary Cancer Testing: Is it Right for You? This workbook is designed to help you decide if hereditary

More information

Yes when meets criteria below. Dean Health Plan covers when Medicare also covers the benefit.

Yes when meets criteria below. Dean Health Plan covers when Medicare also covers the benefit. Genetic Testing for Lynch Syndrome MP9487 Covered Service: Prior Authorization Required: Additional Information: Yes when meets criteria below Yes-as shown below Pre and post test genetic counseling is

More information

Prior Authorization. Additional Information:

Prior Authorization. Additional Information: Genetic Testing for Lynch Syndrome MP9487 Covered Service: Prior Authorization Required: Additional Information: Yes when meets criteria below Yes-as shown below Pre and post test genetic counseling is

More information

Key Recommendations. Gynecologic management of women with inherited risk of gynecologic cancer. HBOC related genes. I have nothing to disclose

Key Recommendations. Gynecologic management of women with inherited risk of gynecologic cancer. HBOC related genes. I have nothing to disclose Gynecologic management of women with inherited risk of gynecologic cancer C. Bethan Powell MD Kaiser Permanente Northern California Gynecologic Oncology Program I have nothing to disclose Key Recommendations

More information

Camelia Davtyan, MD, FACP Clinical Professor of Medicine Director of Women s Health UCLA Comprehensive Health Program

Camelia Davtyan, MD, FACP Clinical Professor of Medicine Director of Women s Health UCLA Comprehensive Health Program Camelia Davtyan, MD, FACP Clinical Professor of Medicine Director of Women s Health UCLA Comprehensive Health Program A B C D USPSTF recommends the service. There is high certainty that Offer or provide

More information

Management of Endometrial Hyperplasia

Management of Endometrial Hyperplasia Management of Endometrial Hyperplasia I have nothing to disclose. Stefanie M. Ueda, M.D. Assistant Clinical Professor UCSF Division of Gynecologic Oncology Female Malignancies in the United States New

More information

Hereditary Colorectal Cancer

Hereditary Colorectal Cancer A Patient s Guide to risk assessment Hereditary Colorectal Cancer Hereditary Cancer Testing: Is it Right for You? This workbook is designed to help you decide if hereditary cancer testing is right for

More information

FAMILIAL COLORECTAL CANCER. Lyn Schofield Manager Familial Cancer Registry

FAMILIAL COLORECTAL CANCER. Lyn Schofield Manager Familial Cancer Registry FAMILIAL COLORECTAL CANCER Lyn Schofield Manager Familial Cancer Registry Cancer in WA 2004 4000 3500 ASPR, rate per 100,000 3000 2500 2000 1500 1000 Male incidence Female incidence Male mortality Female

More information

WELCOME. Taking Care of Your Health. April 30, 8 am to noon

WELCOME. Taking Care of Your Health. April 30, 8 am to noon WELCOME Taking Care of Your Health April 30, 8 am to noon Cancer: Know Your Risk Emily Kuchinsky, MS, CGC, Certified Genetic Counselor Sporadic Cancer Lifetime Probability- Women Family Cluster Risk factors

More information

OVARIAN CANCER Updates in Screening, Early Detection and Prevention

OVARIAN CANCER Updates in Screening, Early Detection and Prevention UW MEDICINE SUSAN PATRICIA TECK MEMORIAL LECTURE October 2017 OVARIAN CANCER Updates in Screening, Early Detection and Prevention BARBARA GOFF, MD Seattle Gynecologic Society March 2018 OVARIAN CANCER

More information

THE MODERN GYNECOLOGIC EXAMINATION & SCREENING FOR GYNECOLOGIC MALIGNANCIES

THE MODERN GYNECOLOGIC EXAMINATION & SCREENING FOR GYNECOLOGIC MALIGNANCIES THE MODERN GYNECOLOGIC EXAMINATION & SCREENING FOR GYNECOLOGIC MALIGNANCIES Denise Uyar, MD Associate Professor OB/GYN Chief Gynecologic Oncology Medical College of Wisconsin April 12, 2019 NO DISCLOSURES

More information

Endometrial Cancer in Thai Women aged 45 years or Younger

Endometrial Cancer in Thai Women aged 45 years or Younger RESEARCH COMMUNICATION Endometrial Cancer in Thai Women aged 45 years or Younger Jitti Hanprasertpong 1 *, Suchada Sakolprakraikij 1, Alan Geater 2 Abstract The aim of this retrospective study was to clarify

More information

Subject: Genetic Testing for Lynch Syndrome and Other Inherited Colon Cancer Syndromes

Subject: Genetic Testing for Lynch Syndrome and Other Inherited Colon Cancer Syndromes 05-82000-31 Original Effective Date: 10/15/01 Reviewed: 10/25/18 Revised: 11/15/18 Subject: Genetic Testing for Lynch Syndrome and Other Inherited Colon Cancer Syndromes THIS MEDICAL COVERAGE GUIDELINE

More information

Early View Article: Online published version of an accepted article before publication in the final form.

Early View Article: Online published version of an accepted article before publication in the final form. : Online published version of an accepted article before publication in the final form. Journal Name: International Journal of Case Reports and Images (IJCRI) Type of Article: Case Report Title: Sigmoid

More information

10/25/2011 OBJECTIVES Cancer Screening in the United States, 2011 A Review of Current American Cancer Society Guidelines and Issues in Cancer Screenin

10/25/2011 OBJECTIVES Cancer Screening in the United States, 2011 A Review of Current American Cancer Society Guidelines and Issues in Cancer Screenin OBJECTIVES Cancer Screening in the United States, 2011 A Review of Current American Cancer Society Guidelines and Issues in Cancer Screening Kathy Gray, DNP, CRNP, FNP-BC Cancer Screenings and Guidelines

More information